Differences in efficacy, mechanism and indications between molotinib/mometinib and ruxolitinib tablets

Momelotinib and ruxolitinib are both used to treat myelofibrosis, Targeted drugs for myeloproliferative tumors such as MF), although both belong to the JAK (Janus kinase) inhibitor class, there are many differences in molecular mechanisms, therapeutic advantages, scope of indications, and side effect spectrum. A comprehensive understanding of the differences between these two drugs can help doctors develop more personalized treatment plans for patients.

From the perspective of its mechanism of action, ruxolitinib is the first dual JAK1/JAK2 inhibitor approved for marketing. It mainly reduces the production of pro-inflammatory factors by inhibiting the JAK-STAT signaling pathway, thereby alleviating splenomegaly and systemic symptoms in patients with myelofibrosis. Its efficacy has been verified in many international clinical studies such as COMFORT-I and COMFORT-II, and it is a foundational drug for the treatment of myelofibrosis. However, ruxolitinib cannot reverse myelofibrosis itself, and its long-term use is often accompanied by hematopoietic suppression side effects such as neutropenia and thrombocytopenia, which is an important medication limitation for MF patients with existing anemia.

Molotinib is a new generation of JAK1/JAK2/ACVR1 triple-target inhibitor, which has a broader spectrum of action than ruxolitinib. Its unique feature is that it can simultaneously inhibit the ACVR1 (Activin A receptor type 1) signaling pathway, which is closely related to the synthesis of hepcidin (hepcidin). By downregulating hepcidin levels, molotinib can improve patients' iron metabolism and erythropoiesis, thereby significantly improving anemia symptoms associated with myelofibrosis, a clinical advantage that ruxolitinib cannot achieve. Therefore, molotinib is particularly suitable for MF patients with moderate to severe anemia, which is often ignored in previous treatment options.

In terms of indications, ruxolitinib has been approved by the FDA and the China State Food and Drug Administration for the treatment of moderate to severe myelofibrosis and xeroderma-like disease (GVHD) and other diseases, and is widely used in clinical applications. Molotinib was approved by the US FDA in 2023 for the treatment of moderate-to-high-risk myelofibrosis adult patients with moderate to severe anemia, especially for patients who have previously received JAK inhibitor treatment or are intolerant to treatment. Its approval marks the entry into an era of more precise management in the field of MF treatment.

In terms of efficacy, there have been multiple phase III clinical studies (such asMOMENTUM study) showed that molotinib was not inferior to ruxolitinib in relieving splenomegaly and improving symptoms, and was more outstanding in correcting anemia. The study showed that the blood transfusion independence rate of patients in the molotinib group was significantly better than that in the control group (using danazol as a control), suggesting that it has unique advantages in improving hematopoietic function. In addition, molotinib can reduce blood transfusion dependence and improve patients' quality of life and long-term survival rate.

As for tolerability and side effects, although both are JAK inhibitorsmolotinib has a better overall safety profile. In published clinical studies, molotinib-induced cytopenias were relatively mild, and its anemia-relieving effect also reduced the need for exogenous red blood cell transfusions. Common adverse reactions include headache, diarrhea and nausea, and the drug is generally well tolerated. In contrast, although ruxolitinib is effective, it is more likely to cause thrombocytopenia and neutropenia in the early stages of treatment, requiring frequent blood routine monitoring.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib